Clark Capital Management Group Inc. Increases Stock Position in Cencora, Inc. $COR

Clark Capital Management Group Inc. grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 2.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 251,467 shares of the company’s stock after purchasing an additional 4,924 shares during the period. Clark Capital Management Group Inc. owned approximately 0.13% of Cencora worth $78,591,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of COR. Vestcor Inc boosted its stake in shares of Cencora by 0.5% in the third quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after buying an additional 28 shares in the last quarter. Cornerstone Wealth Group LLC raised its position in Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after acquiring an additional 30 shares in the last quarter. Security Financial Services INC. lifted its holdings in Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after acquiring an additional 33 shares during the period. Hemington Wealth Management lifted its holdings in Cencora by 12.0% in the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after acquiring an additional 35 shares during the period. Finally, Quadcap Wealth Management LLC boosted its position in shares of Cencora by 1.5% during the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after purchasing an additional 36 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on COR shares. Bank of America lowered their price target on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a report on Tuesday, January 13th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Finally, Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average target price of $399.00.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is owned by corporate insiders.

Cencora Price Performance

Cencora stock opened at $349.69 on Friday. The firm has a market capitalization of $68.03 billion, a PE ratio of 42.03, a P/E/G ratio of 1.63 and a beta of 0.68. Cencora, Inc. has a 52 week low of $252.49 and a 52 week high of $377.54. The firm’s 50-day simple moving average is $355.58 and its 200 day simple moving average is $338.47. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period last year, the firm posted $3.73 EPS. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.